CO-TECHSTARS
20.4.2022 14:02:25 CEST | Business Wire | Press release
Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, announces two strategic and operational leaders who will join the global management team effective immediately. Aparna Ramaswamy will serve as the new Chief Human Capital Officer and Kimberly Smith has been appointed to the newly formed role as Chief Capital Formation Officer, both positions report to CEO, Maëlle Gavet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005309/en/
“The best capital - whether human or financial - will pave the way for Techstars in its ambition to become the largest pre-seed investor," said Gavet. "These two deeply talented and experienced operational leaders will help Techstars continue its growth worldwide for our proven and scalable investment business."
As the new Chief Human Capital Officer, Ramaswamy has experience across a diverse portfolio of global businesses and industries/sectors including financial services, oil and gas, security, aviation, and public education. She has a recognized track record of shaping change through a strategic approach of aligning people and culture to enable businesses to scale and solve complex problems. In her most recent role as Chief Human Capital Officer for Success Academy Charter Schools in New York City, she introduced an innovative two-year leadership fellows program (Robertson Leadership Fellows) to accelerate and build the school leadership pipeline at scale and also created and led the first Inclusion Council and DEI commitments for a network of 47 public charter schools serving 20,000 children across four NYC boroughs. With Techstars’ recent announcement , launching nine diverse-led accelerators programs in partnership with J.P. Morgan, Ramaswamy’s experience in building and leading DE&I related initiatives at scale will be invaluable to the organization.
Prior to her most recent leadership role with Success Academy Charter Schools, Ramaswamy served as Co-Head of Human Resources at Bridgewater Associates and before that, spent 14 years at General Electric (GE) in progressively larger global Human Resources leadership roles across multiple businesses and industries. Based in Stamford, Connecticut, she plans to bring to Techstars her broad and varied range of global experience in talent acquisition, leadership capacity building, talent management, and total rewards, to reinforce operational excellence and deliver on Techstars’ key strategic objectives.
Ramaswamy received a Bachelor of Arts in Sociology and Psychology from St. Xavier’s College in Mumbai, India, a Master of Arts in Sociology from the University of Mumbai, India, and a Master of Business Administration from the University of Michigan Ross School of Business. In her free time, she serves on the American India Foundation Tri-State Board and is a member of the Vitalize VC Angels investment community, and the Chief Network.
Named as Techstars’ first Chief Capital Formation Officer, Smith joined the company in September 2021 and immediately began making an impact through her influence with prospective and existing investors and Limited Partners (LPs). She was integral in helping the organization close the Advancing Cities fund last month.
Based in New York City, she will be responsible for Tecshstars’ fundraising and investor relations while cultivating relationships with current and future investors - both traditional institutional LPs as well as individuals and strategic investors. Smith has spent her career raising money in the investment management sector and before joining Techstars, spent 15+ years with Owl Creek Asset Management, a NY-based event driven hedge fund, where she was a Partner and responsible for raising and retaining billions of investor capital. She has also held leadership positions in Investor Relations and Marketing at Davidson Kempner, traded coffee and sugar in the Global Futures group at ABN AMRO and got her start in finance working at Ziff Brothers.
Smith received her Bachelor of Arts from Middlebury College and her Masters of Business Administration from Fordham University. She is also the Chair of both the Board of Trustees and the Investment Committee at the Ethical Culture Fieldston School in New York City.
Following four other executive appointments within the last year, Techstars is taking bold and ambitious steps toward bringing together an industry team of leaders focused on building and growing a world-class investment business at scale.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 3,000 companies with a combined market cap of more than $172B. www.techstars.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
